Evidence map›Paper›PMID 40687933›Full record

ArticleJournal of virus eradication2025

Achieving the global agenda toward HIV cure calls for establishing a research-for-cure academy in West and Central Africa.

Aude Christelle Ka'e, Collins Ambe Chenwi, Livo Esemu, Hillary Tene, Romeo Djounda, Bouba Yagai, Aubin Nanfack, Alex Durand Nka, Naomi-Karell Etame, Ezechiel Ngoufack Jagni Semengue and 39 more

Abstract read
In one paragraph

Article in Journal of virus eradication, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Aude Christelle Ka'eChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Collins Ambe ChenwiChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Livo EsemuResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Hillary TeneResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Romeo DjoundaResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Bouba YagaiChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Aubin NanfackChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Alex Durand NkaChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Naomi-Karell EtameChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Ezechiel Ngoufack Jagni SemengueChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Celestin GodweResearch Centre for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon.
Honore AwanakanResearch Centre for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon.
Fon Abongwa AchoElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Yaoundé, Cameroon.
Caroline MoforPartners for Relief and Development Organization (PARDO), Yaoundé, Cameroon.
Mambo Musi BerylePartners for Relief and Development Organization (PARDO), Yaoundé, Cameroon.
Benoit BissohongONG FIS, Yaoundé, Cameroon.
Jang Joanes TPartners for Relief and Development Organization (PARDO), Yaoundé, Cameroon.
Lum ForgweiChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Rogers Ajeh AwohFaculty of Health Sciences, University of Buea, Buea, Cameroon.
Gregory Edie Halle EkaneFaculty of Health Sciences, University of Buea, Buea, Cameroon.
R Brad JonesWeill Cornell Medicine Graduate School of Medical Sciences, New York, USA.
Marcel TongoResearch Centre for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon.
Almoustapha-Issiaka MaigaFaculty of Pharmacy, University of Technical Sciences and Technologies of Bamako, Bamako, Mali.
Thomas ToniCEDRES Molecular Biology Laboratory, Abidjan, Republic of Côte d'Ivoire.
Adawaye ChatteFaculté des Sciences de la santé humaine, Université de N'Djaména, N'Djaména, Chad.
Christian MangalaNational Public Health Laboratory, Libreville, Gabon.
Denis Maulot BangolaNational Public Health Laboratory, Libreville, Gabon.
Abou Abdallah Malik DiouaraÉcole Supérieure Polytechnique (ESP), Université Cheikh Anta DIOP (UCAD), Dakar, Senegal.
Djibril WadeInstitut de Recherche en Santé, de Surveillance Épidémiologique et de Formations (IRESSEF), Dakar, Senegal.
Elvis TemfackClinical Research, Centre for Diseases Control and Prevention, Addis Ababa, Ethiopia.
Sofonias Kifle TessemaDiagnostics and Surveillance, Centre for Diseases Control and Prevention, Addis Ababa, Ethiopia.
Erick Ntambwe KamanguDepartment of Basic Sciences, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Christian Diamant Mossoro-KpindeFaculté des Sciences de La Santé, Université de Bangui, Bangui, the Central African Republic.
Mobereade AyokamnmiDepartment of Programs, Association for Reproductive and Family Health, Ibadan, Oyo State, Nigeria.
Laure Stella Ghoma LinguissiInstitut National de Recherche en Sciences de La Santé (IRSSA), Brazzaville, Republic of the Congo.
Charles KouanfackResearch Centre for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon.
Alexis NdjoloChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Souleymane TassembedoClinical Research Department, Centre, MURAZ, Bobo-Dioulasso, Burkina Faso.
Vittorio ColizziChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.
Diana BoraschiShenzhen Institute of Advanced Technology, Chinese Academic of Science, Shenzhen, China.
Krista L DongRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Karine DubéDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego (UCSD), San Diego, USA.
Nicaise NdembiInternational Vaccine Institute, Kigali, Rwanda.
Steven G DeeksResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Caroline T TiemessenResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Thumbi Ndung'uResearch-for-cure Academy, International AIDS Society, Johannesburg, South Africa.
Carlo-Federico PernoBambino Gesu Pediatrics Hospital Centre, Rome, Italy.
Deborah PersaudDepartment of Pediatrics, Johns Hopkins University School of Medicine, Maryland, USA.
Joseph FokamChantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite global efforts to eliminate HIV as a public health threat, sub-Saharan Africa (SSA) still harbours about the highest burden of the pandemic, home to around 70 % of people living with HIV with limited contribution in the field of HIV cure research, especially in West and Central Africa (WCA). This gap is mainly due to challenges that researchers of this region are facing in initiating and advancing HIV cure research locally, with lesser commitment from the French-speaking countries. Furthermore, capacity-building of early career scientists on HIV cure research remains constrained due to limited awareness and language barriers to existing opportunities. Even though HIV non-B subtypes represent 89 % of circulating subtypes worldwide, cure research has been extensively focused on subtype B (prevalent in America and Europe). Interestingly, WCA (known as HIV pandemic epicentre with a broad genetic diversity) offers a unique landscape for cure research with a likelihood of generalisability across various HIV subtypes. This viewpoint discusses the importance of establishing an HIV Cure Academy for WCA to support scientists, policymakers and community stakeholders from French-speaking countries in contributing to the global efforts towards HIV cure. Building on discussions, the establishment of an "HIV Cure Academy" emerges as a hallmark to: (i) raise awareness, (ii) build capacity, (iii) address scientific gaps, (iv) develop networks, and (v) foster advocacy and policy-briefing on integrating HIV cure research into national HIV agenda. The Academy is envisioned as a hub, facilitating relationships between community-based organizations, people living with HIV (PLHIV), research institutions and decision makers. This hub will also champion the "Advocacy for Cure" agenda in the sub-region, enhance multidisciplinary approach to identify local HIV cure research priorities that address the global problem. Of prime importance, research priorities in WCA include: (i) the measurement and characterization of viral reservoirs; (ii) investigation in immune responses including bNAbs, T-cell function, cytokines profiles and hosts genetic factors; (iii) identification of elite and post-treatment controllers; (iv) development of accessible technologies for point-of-care HIV DNA testing, biomarker detection, and latency-modifying agents to support functional cure strategies; (v) innovation in cost-effective and scalable therapeutic interventions suitable for low-resource settings; (vi) the strengthen of community involvement through citizen science, address ethical considerations, and engage PLHIV in the co-design of cure research initiatives; (vii) the establishment of regional training platforms, such as a Research-for-Cure Academy, to enhance scientific capacity and collaboration in West and Central Africa. Following the model of the International AIDS Society (IAS) Research-for-cure academy, the WCA HIV Cure Academy represents a key hub in achieving the goals of HIV cure, through local actions that contribute to addressing a global problem.

Identifiers

PMID40687933
PMCPMC12272123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.